These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 23901839

  • 1. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
    Burns JC, Song Y, Bujold M, Shimizu C, Kanegaye JT, Tremoulet AH, Franco A.
    Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
    [Abstract] [Full Text] [Related]

  • 2. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.
    J Rheumatol; 2012 Apr 17; 39(4):864-7. PubMed ID: 22337241
    [Abstract] [Full Text] [Related]

  • 4. Intravenous Immunoglobulin Therapy Restores the Quantity and Phenotype of Circulating Dendritic Cells and CD4+ T Cells in Children With Acute Kawasaki Disease.
    Wang N, Chen Z, Zhang F, Zhang Q, Sun L, Lv H, Wang B, Shen J, Zhou X, Chen F, Zhang B, Meng L, Zhou H, Bai Z, Huang J.
    Front Immunol; 2022 Apr 17; 13():802690. PubMed ID: 35222381
    [Abstract] [Full Text] [Related]

  • 5. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O.
    J Pediatr; 2008 Dec 17; 153(6):833-8. PubMed ID: 18672254
    [Abstract] [Full Text] [Related]

  • 6. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.
    Burns JC, Touma R, Song Y, Padilla RL, Tremoulet AH, Sidney J, Sette A, Franco A.
    Autoimmunity; 2015 May 17; 48(3):181-8. PubMed ID: 25822882
    [Abstract] [Full Text] [Related]

  • 7. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL, Zhao SL.
    Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
    [Abstract] [Full Text] [Related]

  • 8. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
    Turk J Pediatr; 2019 Oct 11; 61(5):648-656. PubMed ID: 32104995
    [Abstract] [Full Text] [Related]

  • 9. Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?
    Davies S, Gold-von Simson G.
    Pediatr Cardiol; 2013 Oct 11; 34(7):1756. PubMed ID: 23771701
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
    Wang L, He M, Wang W, Li S, Zhao G.
    Eur J Pediatr; 2024 Apr 11; 183(4):1765-1776. PubMed ID: 38240765
    [Abstract] [Full Text] [Related]

  • 11. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 11; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 12. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.
    Ye Q, Gong FQ, Shang SQ, Hu J.
    Clin Immunol; 2016 Oct 11; 171():25-31. PubMed ID: 27519954
    [Abstract] [Full Text] [Related]

  • 13. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
    Ogihara Y, Ogata S, Nomoto K, Ebato T, Sato K, Kokubo K, Kobayashi H, Ishii M.
    Pediatr Res; 2014 Sep 11; 76(3):287-93. PubMed ID: 24964229
    [Abstract] [Full Text] [Related]

  • 14. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
    Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
    [Abstract] [Full Text] [Related]

  • 15. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S.
    Contemp Clin Trials; 2019 Apr 15; 79():98-103. PubMed ID: 30840903
    [Abstract] [Full Text] [Related]

  • 16. Infliximab as a novel therapy for refractory Kawasaki disease.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS.
    J Rheumatol; 2004 Apr 15; 31(4):808-10. PubMed ID: 15088313
    [Abstract] [Full Text] [Related]

  • 17. Evolution of laboratory values in patients with Kawasaki disease.
    Tremoulet AH, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC.
    Pediatr Infect Dis J; 2011 Dec 15; 30(12):1022-6. PubMed ID: 21817952
    [Abstract] [Full Text] [Related]

  • 18. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW.
    J Pediatr; 2011 Apr 15; 158(4):644-649.e1. PubMed ID: 21129756
    [Abstract] [Full Text] [Related]

  • 19. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 Apr 15; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 20. Management of acute and refractory Kawasaki disease.
    Tacke CE, Burgner D, Kuipers IM, Kuijpers TW.
    Expert Rev Anti Infect Ther; 2012 Oct 15; 10(10):1203-15. PubMed ID: 23199405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.